A CYP2C9-dependent endothelium-derived hyperpolarizing factor (EDHF) controls blood flow in many microvascular beds of various species by targeting vascular smooth muscle potassium channels. Since platelets express the same channels, we tested whether EDHF hyperpolarizes platelets and exerts an antithrombotic function in vivo.
Introduction
The continuous release of nitric oxide (NO), prostacyclin, and endothelium-derived hyperpolarizing factor (EDHF) underlies the pronounced vasomotor function of the endothelium in vivo. 1, 2 It is well established that NO and prostacyclin are also released into the vascular lumen and exert inhibitory actions on platelets. 3, 4 It is, however, still unclear, whether EDHF is also released in sufficient amounts in order to exert antiplatelet activity in vivo. In a previous in vitro study, we showed hyperpolarization of human platelets by epoxyeicosatrienoic acids (EETs), leading to inhibition of platelet adhesion to cultured human endothelial cells. 5 An established source of EETs in the vasculature is the 2C9 isoform of the enzyme cytochrome p450 epoxygenase (CYP2C9). 6 Stable overexpression of CYP2C9 in EA.hy926 cells, a cell line with some properties of vascular endothelium, led to a release of EETs into the extracellular space and inhibition of platelet adhesion in vitro. 5 Platelets are indeed a potential target for EETs and a CYP2C-dependent EDHF, because they express calcium-activated potassium channels (K Ca channels). These channels are reportedly involved in EDHF-mediated vascular smooth muscle relaxation. 5, 7 In addition, we and others have observed that platelet hyperpolarization has the potential to directly reduce platelet activation. 5, 8, 9 However, it remains to be shown, whether there is a continuous release of EDHF in vivo and whether in view of the diluting effect of streaming blood the arteriolar endothelium releases sufficient amounts of EDHF to inhibit platelet activity as assessed by platelet interaction with the vessel wall in vivo. If so, this factor could be of significant importance not only for the endogenous protection from thrombotic disease but also atherosclerosis since activation of platelets contributes to the development of cardiovascular disorders. 10, 11 Since the functional significance of EDHF for vessel dilation in comparison to other endothelium-derived factors increases with decreasing vessel size, 12, 13 this could be one explanation for the astounding fact that microvessels do not show atherosclerosis.
We therefore tested in vivo whether a highly specific inhibitor of CYP2C9 is able to reduce platelet activity in arterioles consistent with a continuous influence of EDHF on platelets in the microcirculation. We also sought to compare the relative in vivo role of EDHF with NO in the microvascular endothelium and addressed the question whether each endothelial factor could compensate for the lack of the other one. To understand the mechanism of action of EDHF, we additionally investigated in vitro whether cultured endothelial cells actually release an EDHF in a CYP2C9-dependent manner and whether this factor could affect platelet membrane potential and function.
Methods

Analysis of platelet-vessel wall interactions and firm platelet adhesion in vivo
Platelet-vessel wall interaction (PVWI) including platelet adhesion and rolling was assessed in the dorsal skinfold chamber model in the microcirculation of hamsters as described previously.
14 Experiments were performed not sooner than the day after implanting the chambers in Golden Syrian hamsters. Briefly, platelet-rich plasma (PRP) was prepared from blood samples derived from healthy volunteers as described. 15 Platelets were labelled by incubation of PRP with calcein-AM (5 mmol/L) in the presence of iloprost (10 ng/mL), resuspended in platelet buffer (138 mmol/L sodium chloride, 2.7 mmol/L potassium chloride, 12 mmol/L sodium hydrogen carbonate, 400 mmol/L disodium phosphate, 1 mmol/L magnesium chloride, 5 mmol/L D-glucose, and 5 mmol/L HEPES) to obtain a final concentration of 400 000/mL, and a total amount of 2 Â 10 8 platelets were intravenously injected via jugular vein catheters. Intravital fluorescence microscopy was performed using a modified microscope (Zeiss Axiotech Vario, Germany). Images recorded with a digital camera (C8484, Hamamatsu, Germany, image frequency: 14.5/s) and analysed using SimplePCI TM software (Compix, USA). After recording platelet behaviour in 4 -8 arterioles for 30 s, velocities of trace lengths of single platelets were measured offline and individual platelet velocities calculated as previously described, and PVWI were classified according to platelet velocity distributions.
14 The extent of PVWI was then depicted in frequency histograms that were normalized to the maximal platelet speed within a vessel. In these histograms, a rightward shift in distribution expresses decreased PVWI, whereas a leftwards shift signalizes enhanced PVWI and transient adhesion/tethering at the vessel wall. Firm adhesion of a platelet occurred by definition when a platelet localized at the vessel wall showed no movement over an observation period of more than 10 s. Vessels with irregular flow were excluded from analysis. The method has previously been described in detail. 14 Experiments were conducted either under the indicated treatments or with sham solution, for which the respective diluents were used. To inhibit endothelial NO synthase or CYP2C9, prewarmed MOPS-buffer containing 100 mmol/L of N-nitro-L-arginine (L-NA) or 30 mmol/L of sulfaphenazole, respectively, were superfused over dorsal skinfold chambers for 30 min. In experiments involving EETs, the 11,12-EET stereoisomer (10 mmol/L) was superfused for 10 min before image acquisition. All experiments were conducted in full accordance with the German animal protection law. Written informed consent was obtained from all blood donors.
Endothelial cell culture and generation of endothelial supernatants
Human umbilical vein endothelial cells (HUVEC) were harvested from human umbilical cords as previously described. 5 Cells were grown in medium 199 (Sigma, Deisenhofen, Germany) supplemented with 20% newborn calf serum (Biomol, Hamburg, Germany) and 20% endothelial growth medium (Promocell, Heidelberg, Germany). During and immediately after the harvesting procedure, all buffers and media used for cell culture except those used for control experiments were mixed with nifedipine (100 nmol/L) and b-naphthoflavone (3 mmol/L), both of which have previously been described to be inducers of CYP2C9, 16 to enhance expression of CYP2C9. Sham solution was added to those cells used for control experiments. Immediately after isolation of HUVEC, cells from one identical cord were separated into two different portions, one of which was from then on treated with sham solution containing media, the other was continued to be incubated with nifedipine/b-naphthoflavone. After confluence was reached, cells were preincubated with
100 mmol/L) and indomethacin (20 mmol/L) for 30 min, and, if indicated stimulated with bradykinin (100 nmol/L) for 5 min. In experiments using sulfaphenazole (30 mmol/L), cells were incubated with the respective agent for 30 min, whereas preincubating L-NA and indomethacin. After stimulation with bradykinin or sham solution, equal amounts of platelet buffer, supplemented with 1 mmol/L CaCl 2 , were added and supernatants collected 30 min incubation at 378C. Cells were then dispatched and supernatants used to assess for a platelet hyperpolarizing effect or content of EETs.
RT-PCR
The mRNA expression of cytochrome P450 2C8/9 isoform in cultured HUVEC was determined by RT-PCR. To isolate total mRNA, Trizol reagent (Life Technologies, Karlsruhe Germany) was added to the endothelial cells, which were gently detached using a scraper. Isolation of RNA was performed according to the manufacturer's description. To control for proper isolation a 1% agarose RNA gel was run; and 1 mg of total RNA was subjected to the reverse transcriptase polymerase chain reaction using a one step titan RT-PCR kit (Roche, Germany). Primers used were (5 0 !3 0 ) cct tgg gga tga ggt agt tt for CYP2C8/9 antisense and aga caa cga gca cca ctc tg for CYP2C8/9 sense (MWG Biotech, Ebersberg, Germany).
Assessment of platelet membrane potential changes
Platelet membrane potential was assessed using the potential-sensitive fluorescent dye DiBAC 4 (3). 200 000 WP/mL were incubated with 500 nmol/L of DiBAC 4 (3) for 30 min at darkness and room temperature (RT) in the presence of 10 ng/mL Iloprost (Schering, Berlin, Germany). After addition of 1 mmol/L CaCl 2 , they were exposed to the respective substances or supernatants and fluorescence change were measured immediately, as well as after 10 min to assess steady state values of the membrane potential. On the basis of the Nernst equation and the assumption that the intracellular potassium concentration of platelets was 140 mmol/L and that their membrane potential is close to the K þ -equilibrium potential in the presence of the potassium ionophore valinomycin (2 mmol/L), resting platelet membrane potential of washed human platelets was calculated to be approximately 257 mV. Calibration curves were obtained before each measurement that allowed to calculate absolute values of membrane potential.
Platelet alpha granule release
Platelets in PRP (300 mL) were incubated with the endothelial cell supernatants or potassium channel blockers or both (EETs/EDHF and potassium channel blockers) for 10 min each, followed by stimulation with ADP (20 mmol/L). After the experiments were finished, platelets were fixed in 5% formaldehyde (w/v) and pelleted. Staining was consecutively performed using anti-CD62P-RPE (Serotec, Oxford, UK) for 15 min at RT and darkness. After this, platelets were pelleted, washed once, and fluorescence intensity measured using a FACScan flow cytometer (Becton Dickinson, Franklin Lakes, USA). Data were analysed using CellQuest TM software (Becton Dickinson). Activation was expressed as per cent change compared with the fluorescence intensity of control samples.
Platelet adhesion to HUVEC in vitro
Adhesion of washed platelets to confluent HUVEC cultured in 24-well dishes was assessed as described previously. 5 Briefly, adhesion of human platelets to HUVEC of the first subpassage was assessed using platelets stained with calcein-AM (5 mmol/L). After mechanically inducing platelet adhesion to HUVEC by centrifugation, non-adherent platelets were removed by three washing steps, and fluorescence in each well was measured using a 24-well plate fluorescence reader (SpectraFluor, Tecan, Maennedorf, Switzerland, excitation wavelength: 488 nm, emission wavelength: 515 nm). Firm platelet adhesion was determined as changes of fluorescence intensity as expressed as% of control. To assess the effectiveness of inhibition of adhesion in this assay, abciximab (0.2 mg/mL) was added to some wells of endothelial cells immediately before centrifugation.
Materials
The restriction endonuclease BclI was from Fermentas (St Leon-Rot, Germany). DiBAC 4 (3) was from Molecular Probes (Leiden, The Netherlands). EETs were from Cayman Chemicals (Hamburg, Germany). All other substances were obtained from Sigma Chemicals Co.
Statistical analysis
All data are expressed as means + SEM. Data were analysed using either one-way ANOVA with Bonferroni's correction for multiple comparisons or student's t-test for unpaired data as appropriate. Potential differences between platelet velocity distributions were analysed using the Kolmogorov-Smirnov test. Differences were considered significant when the error probability level was P , 0.05. Figure 1 ). The mean diameter of all analysed arterioles amounted to 55.7 + 0.9 mm (n ¼ 261). All dosages used have been proven before to reduce basal diameters in local superfusion on hamster tissue in prior studies.
The CYP2C9-dependent factor inhibits firm platelet adhesion to the vessel wall in vivo
When assessing the amount of firmly adherent platelets at the vessel wall following inhibition of NO synthesis or CYP2C9, we did not observe firmly adherent platelets at all in control animals (n ¼ 38). However, superfusion with L-NA caused a spontaneous firm adhesion of 13.7 + 4.3 platelets per mm 2 (n ¼ 48, P , 0.01 vs. control) and sulfaphenazole superfusion caused a spontaneous firm adhesion of 19.7 + 7.9 platelets per mm 2 (n ¼ 47, P , 0.05 vs.
control, Figure 2A ). Representative images of PVWI and firm platelet adhesion are shown in Figure 2B .
3.3 The CYP2C9 product 11,12-EET inhibits platelet -endothelium interactions in vivo
Addition of 11,12-EET, the previously described product of CYP2C9, to the superfusate elicited a small but significant effect on PVWI in unstimulated arterioles. When 11,12-EET were superfused together with sulfaphenazole for 30 min prior to assessing platelet-endothelium interactions the enhancing effect of sulfaphenazole on PVWI could not be observed any more (P , 0.05, n ¼ 1638 platelets, 27 vessels, five animals, Figure 3 ).
Human endothelial cells expressing CYP2C9 release a platelet-hyperpolarizing factor
Supernatants of HUVEC that had been grown to confluence in the continuous presence of the inducers of CYP2C9, b-naphthoflavone (3 mmol/L), and nifedipine (100 nmol/L), but not control cells, significantly hyperpolarized platelets when stimulated with bradykinin (100 nmol/L), indicating the release of EDHF (from 258 to 273 mV, n ¼ 22, P , 0.05, Figure 4) . EDHF was not effective or present, when these HUVEC were preincubated with the inhibitor of CYP2C9, sulfaphenazole (30 mmol/L, n ¼ 13, P , 0.05, Figure 4 ). In the absence of bradykinin (BK), the supernatants did not cause statistically significant hyperpolarization of platelets (n ¼ 12), neither did supernatants of HUVEC grown without b-naphthoflavone and nifedipine (n ¼ 19). Sulfaphenazole treatment of HUVEC did also not affect platelet membrane potential (n ¼ 13). The expression of CYP2C9 mRNA in HUVEC was confirmed by RT-PCR analysis, it was markedly enhanced after the continuous treatment of cells with b-naphthoflavone and nifedipine. Specificity of the bands was confirmed by restriction enzyme digestion using the restriction enzyme BclI (n ¼ 3, Figure 4 , insert).
The EDHF hyperpolarizes platelets by the activation of IK Ca /BK Ca channels
Hyperpolarization caused by the EDHF-containing HUVEC supernatants could be inhibited by platelet pretreatment with charybdotoxin (50 nmol/L n ¼ 5, P , 0.01, Figure 5 ) a blocker of K Ca channels) of intermediate (IK Ca ) or large conductance (BK Ca ), but not by apamin (500 nmol/L, n ¼ 9, n.s.), an inhibitor of small conductance K Ca channels (SK Ca ). In control experiments, neither sulfaphenazole (30 mmol/L) nor a prostacyclin analogue (iloprost, 10 ng/mL), nor an NO-donor (SNAP, 2 mmol/L) had a measurable effect on platelet membrane potential (data not shown). Nevertheless, both iloprost and SNAP inhibited measured platelet aggregation in PRP (data not shown, measured turbidimetrically on a ChronoLog Aggregometer, Havertown, USA). This suggests that HUVEC, which express CYP2C9, release an EDHFlike factor that hyperpolarizes platelets via IK Ca /BK Ca channels upon bradykinin stimulation.
The EDHF inhibits plateletendothelium interactions through activation of IK Ca /BK Ca channels and prevention of platelet degranulation
In vitro, addition of EDHF-containing supernatants to human platelets decreased their adhesion to cultured HUVEC significantly (by 20 + 6% when compared with non-EDHF-containing supernatants, n ¼ 16, P , 0.01). This was prevented by pretreatment of the platelets with charybdotoxin (50 nmol/L, n ¼ 10, P , 0.01 vs. EDHF alone) (500 nmol/L, n ¼ 6, P , 0.05 vs. EDHF alone), but not by apamin (500 nmol/L, n ¼ 5, Figure 6A) . Pretreatment of the platelets with sulfaphenazole did also not affect the adhesion (data not shown). As a positive control, we used the b 3 -integrin blocker abciximab (0.2 mg/mL), which reduced platelet adhesion by 35 + 4% (n ¼ 17, P , 0.01, Figure 6A) . As a functional assay of platelet activation, we assessed EDHF effects on platelet P-selectin (CD62P) expression by FACS. ADP (20 mmol/L, 3 min, n ¼ 20, P , 0.01) induced a significant increase in platelet CD62P expression compared with sham-treated platelets ( Figure 6B ). EDHF-containing supernatants from HUVEC inhibited this ADP-dependent platelet CD62P expression significantly (n ¼ 9, P , 0.01 vs. ADP).
Discussion
Here we show, for the first time, that pharmacological inhibition of CYP2C9 in the microcirculation in vivo leads to an enhanced interaction of human platelets with the intact endothelium including firm adhesion which is normally never observable in intact arterioles. This finding suggests a continuous release of a CYP2C9-dependent factor from the endothelium into the streaming blood contributing decisively to the antithrombotic properties of the arteriolar endothelium. This factor could not be isolated or measured directly in the microcirculation for obvious reasons but is by definition an EDHF: parallel studies in cultured human endothelium demonstrate that a CYP2C9-dependent factor is released which hyperpolarizes human platelets via activation of IK Ca and/or BK Ca channels. The platelet hyperpolarizing factor most likely is identical with EETs, which are formed by CYP2C9 and which as we have previously shown hyperpolarize human platelets through IK Ca /BK Ca channels. 5 The hyperpolarization reduces platelet activation as shown by the reduced expression of P-selectin in response to ADP. The antithrombotic activity of the CYP2C9-dependent factor in the microcirculation is quantitatively similar to the effects exerted by endogenous NO in the microcirculation. Our data suggest that both factors have additive affects on platelet activity, as derived from the enhanced platelet activation after simultaneous inhibition of both eNOS and CYP2C9. This would be consistent with separate regulation of platelet activity by the two endothelial mediators via two different mechanisms of action. Whether their action was synergistic or additive cannot be decided from our experiments since full dose-response curves for both endothelial dilators evidently cannot be directly obtained. In addition, we cannot exclude that The inhibitor of small conductance K Ca channels (SK Ca channels), apamin (Apa., 500 nmol/L, n ¼ 9, n.s.) had no effect (**P , 0.01 vs. control, # P , 0.05 vs. EDHF, ## P , 0.01 vs. EDHF).
EDHF opposes platelet-endothelium interactions in vivo one endothelial mediator possibly also regulated the release of the other one as shown before in vitro. 17 However, our data clearly
show that in the microcirculation NO and EDHF cannot fully compensate for each other. EDHF is an endothelium-derived factor different from NO and prostacyclin participating in vascular relaxation upon endothelial stimulation by bradykinin, acetylcholine, or shear stress and is probably functionally most important in the microcirculation. 18 -20 NO and prostacyclin are released from endothelial cells and therefore not only exert their effects on the underlying vascular smooth muscle, but also on circulating blood constituents like platelets. 3, 4, 21 The effect of EDHF on blood elements has been studied less extensively, probably because some actions of EDHF could be inhibited by blockade of intercellular gap junction proteins, 22, 23 suggesting that EDHF-like dilations may not always be mediated by a factor. However, gap junctions are unlikely to play a role in our experiments since in the streaming blood, platelets, which probably would not have long enough contact with the endothelium to allow a sufficient transcellular transfer of an inhibitory compound from the endothelium. Of note, there was hitherto no experimental evidence that this factor is continuously released in sufficient amounts to affect circulating blood cells. Even the question whether enough EDHF is released continuously from the non-stimulated endothelium in vivo to affect basal tone has been addressed by only a few studies. However, studies with pharmacological inhibitors suggest that there is a continuous influence of EDHF on basal vascular tone. 24 -27 Our in vivo observations support the concept that a CYP2C9-dependent factor with properties of an EDHF is indeed released and can be transferred to neighbouring blood cells, since it exerts an in vivo functional effect on circulating platelets. The influence of the CYP2C9-dependent factor on platelet-endothelium interactions was not due to a direct action of sulfaphenazole on platelets as shown by the lack of sulfaphenazole effects in isolated platelets. The fact that in vitro we found only enough EDHF to affect the platelets when the endothelium was stimulated with bradykinin does not contradict our conclusion of a continuously released EDHF from unstimulated (i.e. not stimulated by bradykinin or acetylcholine superfusion) endothelium in vivo. In vivo, the endothelium is continuously exposed to shear stress and previous findings show that a CYP2C9-dependent EDHF or EETs are both released from the endothelium not only after stimulation by soluble plasma factors or drugs but also as a response to shear stress. 16,28 -30 In addition, the type of vascular endothelium may account for the amount of EDHF that is potentially generated in vivo. Potentially, microvascular endothelium should produce and release more EDHF than the HUVEC cells used in our experiments. Our in vivo study was conducted in a hamster microcirculatory model. In the present study, we did not show explicitly that the factor is indeed released from the endothelium nor did we show expression of CYP2C9 in these vessels. However in a previous study on isolated small resistance arteries from the hamster, we showed vascular expression of CYP2C9. We also have demonstrated by using antisense treatment of the endothelium that the endothelial stimulator acetylcholine hyperpolarized the vessels in a CYP2C9-dependent manner. 31 In humans, to our knowledge, a CYP2C9-derived EDHF inducing vasodilation has so far been shown in larger vessels only, such as the internal mammary artery or radial arteries. 24, 32 However, as shown here in vitro, numerous studies have previously demonstrated that at least a CYP2C9-dependent or EET-type EDHF can be released from the endothelium and plays a role in various vascular regions of different species. 5,19,32 -34 Moreover, studies in isolated human coronary arteries support the notion that EETs exert potent vasodilating properties in the Hyperpolarization prevents of platelet degranulation prevention of ADP-dependent platelet P-selectin expression was observed, when platelets were pretreated with EDHF-containing supernatants, indicating that the hyperpolarizing effect involved inhibition of platelet degranulation (ADP 20 mmol/L, n ¼ 9) (n ¼ 9, **P , 0.01 vs. control, ## P , 0.01 vs. ADP).
coronary circulation and that their potential enzymatic sources are highly expressed in the human coronary vascular bed. 35 Added the fact that we studied human platelets in our study, which we have previously shown to be functionally intact in the hamster microcirculation, 14 these results may have relevance for human physiology as well.
As to the signalling mechanism by which the CYP2C9-dependent EDHF exerts its effects on platelets, the complete signalling cascade cannot be shown in vivo. We suggest that hyperpolarization-mediated reduction of platelet oxidative stress, which we have previously observed in washed human platelets, is likely involved 36 and may contribute to the decreased platelet P-selectin expression as an indicator for reduced platelet degranulation and activation, respectively. 37 This is most likely a membrane potential dependent effect, as we have previously observed membrane potential-dependent inhibition of platelet degranulation mediated through EETs 5 which act on the same channels as observed in our experiments. Moreover, the in vivo augmentation of platelet activation after sulfaphenazole was reversed by exogenous addition of 11,12-EET in the hamster model. These data are consistent with the idea that the CYP2C9-dependent EDHF may represent an EET. Indeed, the effects of the CYP2C9-dependent EDHF which he had observed in vitro on human platelets mimicked the effects which we have previously described for exogenous EETs. 5 The same similarities exist with regard to K Ca channels which are the targets of the EDHF and of EETs in human platelets. The different effects of potassium channel inhibitors charybdotoxin and apamin are consistent with the hitherto described expression of K Ca channel subtypes in platelets. 7, 8 Although our data suggest that the inhibition of adhesion and of adhesion molecule expression is to some extent membrane potential dependent, membrane potential independent effects potentially contributing to our findings cannot be excluded at present. Possibly, an interaction of the EDHF effects with prostacyclin released from vascular endothelium may also exist. This, however, cannot clearly be investigated in our hamster model, as blockade of endothelial prostacyclin production by non-specific cyclooxygenase inhibitors would also inhibit platelet action. Altogether, inhibition of platelet adhesion to the endothelium by a factor that is sensitive to the highly specific CYP2C9 inhibitor sulfaphenazole suggesting actions of an EDHF could represent an important mechanism of protection in atherosclerotic disease and its thrombotic complications. EDHF is assumed to be of pivotal importance especially in pathologically altered vessels. 38 -41 In such situations, its effect on platelet adhesion might outbalance the lack of other endogenous antiplatelet factors such as NO particularly in the microcirculation, a concept, that remains to be addressed in future studies.
